ClinicalTrials.gg
CompletedNCT02220153Updated Oct 5, 2015

A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers

A Phase 1 interventional study of UCB7665 Intravenous 1 and UCB7665 Intravenous 2 in Healthy, sponsored by UCB Celltech. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-05.

Sponsored by UCB Celltech (part of UCB S.A.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This study is designed to evaluate the safety and tolerability of single ascending doses of UCB7665 administered by intravenous or subcutaneous infusion in healthy subjects.

02

Conditions studied

  • Healthy

Keywords

  • Monoclonal antibody
  • subjects
  • First in human
03

In context

Lead sponsor

UCB Celltech is the lead sponsor of 8 studies on the registry; none are open to participants now.

First submitted after UCB Celltech became part of UCB S.A..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female volunteers of non- who gave their consent to the written form
  • Healthy volunteers in the age between 18 and 64 years old with normal weight as determined by a (BMI) between 18 and 30 kg/m\^2, with a body weight of at least 50 kg for male subjects or 45 kg for female subjects
  • Subjects has blood pressure (BP) and pulse within normal range in a supine position after 5 minutes rest
  • Subject has clinical laboratory test results within the reference ranges of the testing laboratory or test results that are outside the specified ranges and that are deemed as clinically non-significant
  • Subject's (ECG) is considered "normal" or "abnormal" but clinically non-significant

Exclusion criteria

Exclusion Criteria:

  • Subject has had significant blood loss, or has donated blood in excess of 400 mL of blood or blood products within 90 days before Day -2, or plans to donate blood during the clinical study
  • Subject has a total Immuneglobulin G \<7 g/L or >16 g/L at the Screening Visit
  • Subject has \<1.5x10\^9/L and/or lymphocyte count \<1.0x10\^9/L
  • Subject has known viral hepatitis, has a positive test for surface antigen or is virus antibody positive
  • Subject tests positive to (HIV) 1/2 antibodies
  • Subject has a past medical history or family history of primary immunodeficiency
  • Subject is splenectomized
  • Subject has a positive TIGRA (T cell interferon γ release assay) at the Screening Visit. If TIGRA is not available, purified protein derivative (PPD) skin test can be substituted and/or chest x-ray performed within 6 months before the Screening Visit showing no evidence of latent/active Tuberculosis (TB)
  • Subject has past (in the last 12 months ) or present substance abuse/dependence or concurrent medical conditions that in the opinion of the investigator could confound clinical study interpretation or affect the subject's ability to fully participate in the clinical study
  • Subject has a known to any components of the Medicinal Product (IMP)
  • Subject has an active infection or has had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks before the first dose of IMP
  • Subject has 12-lead (ECG) with changes considered to be upon medical review
  • Subject has renal impairment
  • Subject has hepatic impairment
  • Subject has corrected serum calcium of >11.5 mg/dL (>2.9 mmol/L) or \<8.0 mg/dL (\<2.0 mmol/L) at the Screening Visit
  • Subject has active neoplastic disease or history of neoplastic disease within 5 years of entry in the clinical study
  • Subject has any other acute or chronic illness which, in the opinion of the investigator or study physician, could pose a threat or harm to the subjects
  • Subject has received a vaccination within 6 weeks before the Screening Visit or intends to have a vaccination before Day 43 of the Safety Follow-up Period
  • Subject has received any IMP or experimental procedure within 90 days before the first dose of IMP
  • Subject requires a treatment other than Paracetamol during the clinical study
  • Subject is a vulnerable subject (e.g. subject kept in detention) (Declaration of Helsinki, 1996)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    UCB7665 Intravenous 1

    Single dose calculated based on body weight for 60 minutes intravenous infusion.

    Biological: UCB7665 Intravenous 1

  • Experimental
    UCB7665 Intravenous 2

    Single dose calculated based on body weight for 60 minutes intravenous infusion.

    Biological: UCB7665 Intravenous 2

  • Experimental
    UCB7665 Intravenous 3

    Single dose calculated based on body weight for 60 minutes intravenous infusion.

    Biological: UCB7665 Intravenous 3

  • Experimental
    UCB7665 Intravenous 4

    Single dose calculated based on body weight for 60 minutes intravenous infusion.

    Biological: UCB7665 Intravenous 4

  • Experimental
    UCB7665 Intravenous 5

    Single dose calculated based on body weight for 60 minutes intravenous infusion.

    Biological: UCB7665 Intravenous 5

  • Experimental
    UCB7665 Subcutaneous 1

    Single dose calculated based on body weight for 60 minutes subcutaneous infusion.

    Biological: UCB7665 Subcutaneous 1

  • Experimental
    UCB7665 Subcutaneous 2

    Single dose calculated based on body weight for 60 minutes subcutaneous infusion.

    Biological: UCB7665 Subcutaneous 2

  • Placebo comparator
    Intravenous Placebo

    Single dose placebo comparator for each active arm of intravenous infusion.

    Biological: Intravenous Placebo

  • Placebo comparator
    Subcutaneous Placebo

    Single dose placebo comparator for each active arm of subcutaneous infusion.

    Biological: Subcutaneous Placebo

Interventions

  • * Active substance: UCB7665 * Pharmaceutical form: solution * Concentration: 140 mg/mL * Route of Administration: intravenous infusion

  • * Active substance: UCB7665 * Pharmaceutical form: solution * Concentration: 140 mg/mL * Route of Administration: intravenous infusion

  • * Active substance: UCB7665 * Pharmaceutical form: solution * Concentration: 140 mg/mL * Route of Administration: intravenous infusion

  • * Active substance: UCB7665 * Pharmaceutical form: solution * Concentration: 140 mg/mL * Route of Administration: intravenous infusion

  • * Active substance: UCB7665 * Pharmaceutical form: solution * Concentration: 140 mg/mL * Route of Administration: intravenous infusion

  • * Active substance: UCB7665 * Pharmaceutical form: solution * Concentration: 140 mg/mL * Route of Administration: subcutaneous infusion

  • * Active substance: UCB7665 * Pharmaceutical form: solution * Concentration: 140 mg/mL * Route of Administration: subcutaneous infusion

  • BiologicalIntravenous Placebo

    * Active substance: Placebo * Pharmaceutical form: solution * Concentration: 0.9 % saline * Route of Administration: intravenous infusion

  • BiologicalSubcutaneous Placebo

    * Active substance: Placebo * Pharmaceutical form: solution * Concentration: 0.9 % saline * Route of Administration: subcutaneous infusion

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events during the study

    Time frame: Day -1 up to Day 85

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    The value of the maximum plasma concentration will be directly obtained from the observed plasma concentration versus time curves. Pharmacokinetic samples will be taken predose, at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.

    Time frame: Predose (Day 1) up to Day 85

  2. Area under the curve from 0 to infinity (AUC)

    AUC will be calculated using plasma concentrations taken at predose, at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.

    Time frame: Predose (Day 1) up to Day 85

  3. Area under the curve from time 0 to time t, the time of last quantifiable concentration [AUC(0-t)]

    AUC(0-t) will be calculated using plasma concentrations taken at predose, at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.

    Time frame: Predose (Day 1) up to Day 85

  4. Time to reach Cmax (Tmax)

    Tmax will be directly obtained from the observed plasma concentration versus time curves, using plasma concentrations taken at predose, at the end of infusion, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours after start of infusion; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.

    Time frame: Predose (Day 1) up to Day 85

  5. Total Immunoglobulin G (IgG ) concentrations

    Total Immunoglobulin G will be measured at predose, 24, 48, 72, and 96 hours postdose; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.

    Time frame: Predose (Day 1) up to Day 85

  6. Immunoglobulin G1 subclass concentrations

    Immunoglobulin subclass will be measured at predose, 24, 48, 72, and 96 hours postdose; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.

    Time frame: Predose (Day 1) up to Day 85

  7. Immunoglobulin G2 subclass concentrations

    Immunoglobulin subclass will be measured at predose, 24, 48, 72, and 96 hours postdose; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.

    Time frame: Predose (Day 1) up to Day 85

  8. Immunoglobulin G3 subclass concentrations

    Immunoglobulin subclass will be measured at predose, 24, 48, 72, and 96 hours postdose; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.

    Time frame: Predose (Day 1) up to Day 85

  9. Immunoglobulin G4 subclass concentrations

    Immunoglobulin subclass will be measured at predose, 24, 48, 72, and 96 hours postdose; and on Days 7, 10, 13, 16, 19, 22, 29, 43, 57, and 85.

    Time frame: Predose (Day 1) up to Day 85

07

Study locations

1 site
  • 001
    Harrow, Middlesex, United Kingdom
08

References and documents

Publications

  • Kiessling P, Lledo-Garcia R, Watanabe S, Langdon G, Tran D, Bari M, Christodoulou L, Jones E, Price G, Smith B, Brennan F, White I, Jolles S. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. Sci Transl Med. 2017 Nov 1;9(414):eaan1208. doi: 10.1126/scitranslmed.aan1208. Erratum In: Sci Transl Med. 2017 Dec 6;9(419):eaar6448. doi: 10.1126/scitranslmed.aar6448. PubMed 29093180 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2014
First posted
Aug 19, 2014
Start
Jul 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Last update
Oct 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02220153
Lead sponsor
UCB Celltech
Collaborators
Parexel
Responsible party
Sponsor
First posted
Aug 19, 2014
Start date
Jul 2014
Primary completion
Sep 2015
Completion
Sep 2015
Last update
Oct 5, 2015

Study contacts

UCB Clinical Trial Call Center
study director · UCB Pharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion